
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova's sales have experienced significant growth, with reported figures of $803 million in 2024, and management forecasts an increase to between $940 million and $955 million for the upcoming year. The company's strategic focus on cardiopulmonary solutions and neuromodulation devices positions it well within high-demand segments, indicating robust revenue potential. Additionally, projections for the aura6000 device suggest a potential increase in market share and sales, with estimates ranging from $120 million in 2027 to $280 million by 2029 under favorable conditions, contributing positively to LivaNova's growth outlook.
Bears say
LivaNova's financial outlook is negatively impacted by anticipated revenue growth slowing to the low-single digits, primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. The company's operating margins are expected to contract, contributing to earnings falling below market consensus. Additional risks include the potential failure to secure FDA approval for the aura6000, coupled with slower than expected growth and weaker margin improvements in both its Neuromodulation and Cardiopulmonary divisions.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares